Development of New Instruction for Intranasal Drug Administration

Main Article Content

Prayuth Poowaruttanawiwit1
Chattapat Phonkasapsin
Panyaporn Punnapong2
Chanida Chantim
Jiranut Chaibhuddangul
Jiraporn Puwarattanawiwit
Kwanchai Rattanamanee
Shakrit Rimpanit
Janyut Srihirun

Abstract

Objective: To develop new instruction for intranasal spray administration. Method: A systematic review was conducted by retrieving related studies, clinical practice guidelines and clinical advices from PubMed, Medline, CENTRAL, Web of Science, Google Scholar, Open Gray, DART-Europe, ThaiLIS, ThaiJO and Thai Index Medicus. The main outcomes of data search were instructions for intranasal administration of decongestant or corticosteroids. Subsequently, the identified instructions were assessed through brainstorming among experts and developed into 5 best methods. They were preliminarily tested in laboratory setting for their efficacy in 10 healthy volunteers by using the modified NU_spiroBreathe (NUB). The outcome of interest was intranasal pressure measured from inhalation through the nose of volunteers during intranasal drug administration together with opinions from experts. One best method was selected and tested in laboratory setting in 20 healthy volunteers to confirm its efficacy. Results: Information gained from systematic review was used to develop 5 different instructions for intranasal drug administration. Experts reached the consensus on the best instruction, which was the one showing the best result in laboratory test. The chosen instruction was “tilt the head until one ear touches the fist placed on a table, then look straight along the arm”. The average intranasal pressures at inhalation measured at the left and right nostrils of healthy volunteers during intranasal drug administration were 34.55± 2.26 and 4.35± 2.86 cmH2O, respectively, when not closing both nostrils and 11.26± 3.75, 10.16± 3.29 cmH2O, respectively, when closing both nostrils. Conclusion: This study provided a new instruction for intranasal drug administration likely to be effective. Further study in patients is warrant.

Article Details

Section
Research Articles

References

Khan DA. Allergic rhinitis and asthma: epidemiology and common pathophysiology. Allergy Asthma Proc 2014; 35: 357-61.

Aring AM, Chan MM. Current concepts in adult acute rhinosinusitis. Am Fam Physician 2016; 94: 97-105.

Dykewicz MS, Wallace DV, Baroody F, Bernstein J, Craig T, Finegold I, et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol 2017 ; 119: 489-511.

Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 2020; 58: 1-464.

Rollema C, van Roon EN, de Vries TW. Inadequate quality of administration of intranasal corticosteroid sprays. J Asthma Allergy 2019; 12: 91-4.

Rollema C, van Roon EM, Schilder AG, de Vries TW. Evaluation of instructions in patient information leaflets for the use of intranasal corticosteroid sprays: an observational study. BMJ Open 2019; 9: e026710.

Seth D, Kamat D. Intranasal steroid therapy for allergic rhinitis. Pediatr Ann 2019; 48: e43-e48.

Petty DA, Blaiss MS. Intranasal corticosteroids topical characteristics: side effects, formulation, and volume. Am J Rhinol Allergy 2013; 27: 510-3.

Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspec tive-a review. Drug Deliv Transl Res 2013; 3: 42-62.

Pharmacy Council of Thailand. Handbook of pharmacy core competency. Nonthaburi: Ministry of Public Health; 2019. p 123.

Assanasen P. Suggestion of intranasal corticoste roids administration technique [online]. 2009 [cited Feb 22, 2019]. Available from: www.rcot.org/datafile /_file/_know ledge/5542d94d26cec5731c5001acb5a 18fa5.pdf.

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE Next Steps Consortium. AGREE II: advancing guideline develop ment, reporting and evaluation in health care. CMAJ 2010; 182: E839-42. doi: 10.1503/cmaj.090449.

Yang ZR, Sun F, Zhan SY. Revised Cochrane risk of bias tool for individually randomized, parallel group trials (RoB2.0)]. Chin J Epidemiol 2017; 38: 1285-91.

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919.

Poowaruttanawiwit P, Rachapradit N, Srihirun J. The design and development of a tool to assess obstruction of the nasal cavity. Thai J of Pediatr 2018; 57: 145-53.

Bateman ND, Whymark AD, Clifton NJ, Woolford TJ. A study of intranasal distribution of azelastine hydrochloride aqueous nasal spray with different spray techniques. Clin Otolaryngol Allied Sci 2002; 27: 327-30.

Tay SY, Chao SS, Mark KT, Wang Y. Comparison of the distribution of intranasal steroid spray using different application techniques. Int Forum Allergy Rhinol 2016; 6: 1204-10.

Benninger MS, Hadley JA, Osguthorpe JD. Techni ques of intranasal steroid use. Otolaryngol Head Neck Surg 2004; 130: 5-24.

Loh CY, Chao SS, Chan YH, Wang DY. A clinical survey on compliance in the treatment of rhinitis using nasal steroids. Allergy 2004; 59: 1168-72.

Benninger M. Diagnosis and management of nasal congestion: the role of intranasal corticosteroids. Postgrad Med 2009; 121: 122-31.

Bridgeman MB. Overcoming barriers to intranasal corticosteroid use in patients with uncontrolled allergic rhinitis. Integr Pharm Res Pract 2017; 6: 109-19.

Ganesh V, Banigo A, McMurran AEL, Shakeel M, Ram B. Does intranasal steroid spray technique affect side effects and compliance? Results of a patient survey. J Laryngol Otol 2017; 131: 991-6.

Rollema C, van Roon EM, Schilder AG, de Vries TW. Evaluation of instructions in patient information leaflets for the use of intranasal corticosteroid sprays: an observational study. BMJ Open 2019; 9: e026710.

Rollema C, van Roon EN, de Vries TW. Inadequate quality of administration of intranasal corticosteroid sprays. J Asthma Allergy 2019; 12: 91-4.

Pharmacy Council of Thailand. Handbook of pharmacy core competency. Nonthaburi: Ministry of Public Health; 2019. p 123.

Harvey R, Katelaris C, Tite C, Young S. Intranasal corticosteroid spray technique [online]. 2010 [cited Apr 2, 2019]. Available from: www.nationalasthma. org .au/living-with-asthma/resources/health-profes sionals/information-paper/intranasal-spray-tech nique.

British Society of Allergy and Clinical Immunology. BSACI guidelines for the management of allergic and non-allergic rhinitis [online]. 2014 [cited Apr 2, 2019]. Available from: www.bsaci.org/LiteratureRe trieve.aspx?ID=129062.

University of Wisconsin Hospitals and Clinics Authority. How to use an inhaler nasal spray [online]. date unknown [cited Apr 2, 2019]. Available from: www.uwhealth.org/healthfacts/ear/6684.html.

Hillingdon Hospitals. How to use a nasal spray for children [online]. 2019 [cited Apr 2, 2019]. Available from: www.thh.nhs.uk/documents/_Patients/Patient Leaflets/paediatrics/How_to_use_a_nasal_spray_for_children.pdf

Health Online Unit, Ministry of Health Malaysia. How to use nasal spray [online]. 2019 [cited Apr 2, 2019]. Available from: www.myhealth.gov.my/en/how-to-use-nasal-spray/?fbclid=IwAR08miG4trk3x3gWkfC6 mw BfDDQC-XNb1dL2FSAQD1Qs-7daa_fsPl0JiX0.

Ministry of Health, Singapore. Aqueous nasal spray [online]. date unknown [cited Apr 2, 2019]. Available from: www.healthhub.sg/a-z/medications/59/Aqueou s-Nasal-Spray.

American Society of Health-System Pharmacists. Triamcinolone nasal spray [online]. 2017 [cited Apr 2, 2019]. Available from: medlineplus.gov/druginfo/m eds/a682791.html.

American Society of Health-System Pharmacists. Budesonide nasal spray [online]. 2018 [cited Apr 2, 2019]. Available from: medlineplus.gov/druginfo/me ds/a601030.html.

American Society of Health-System Pharmacists. Mometasone nasal spray [online]. 2018 [cited Apr 2, 2019]. Available from: medlineplus.gov/druginfo/med s/a602024.html.

American Society of Health-System Pharmacists. Olopatadine nasal spray [online]. 2015 [cited Apr 2, 2019]. Available from: medlineplus.gov/druginfo/med s/a615038.html.

American Society of Health-System Pharmacists. Flunisolide nasal spray [online]. 2016 [cited Apr 2, 2019]. Available from: medlineplus.gov/druginfo/med s/a685022.html.

Advanced ENT and Allergy. Everything you need to know about nasal sprays [online]. date unknown [cited Feb 14, 2019]. Available from: www.advance dentandallergy.com/blog-nasal-sprays.php

Asthma UK and British Lung Foundation Partnership. Hay fever treatment [online]. date unknown [cited Feb 14, 2019]. Available from: www.asthma.org.uk/advice/inhalers-medicines-treatments/other/hay-fever/.

American Society of Health-System Pharmacists. Safe medication [online]. 2014 [cited Jan 30, 2019]. Available from: www.safemedication.com/safemed/ MedicationTipsTools/HowtoAdminister/HowtoUseNasalSpraysProperly

WebMD. Decongestant nasal (oxymetazl) spray, non-aerosol [online]. date unknown [cited Feb 14, 2019]. Available from: www.webmd.com/drugs/2/ drug-54237/decongestant-nasal-oxymetazoline-na sal/details

Glaxo SA, Duero A. How to use an inhaler nasal spray [online]. date unknown [cited Apr 2, 2019]. Available from: www.uwhealth.org/healthfacts/spa nish/6927.pdf

Health Products Regulatory Authority. Dymista leaflet [online]. date unknown [cited Apr 2, 2019]. Available from: www.hpra.ie/img/uploaded/swedocu ments/2191521.

GlaxoSmithKline. Flixonase aqueous nasal spray [online]. 2019 [cited Feb 14, 2019]. Available from: www.medicines.org.uk/emc/files/pil.845.pdf.

Procter & Gamble Company and Affiliates. Iliadin [online]. date unknown [cited Feb 14, 2019]. Available from: www.iliadin.com/th_TH/home/pro ducts/iliadin-classic-005-metered-spray.html

Bayer. Afrin [online]. 2019 [cited Feb 14, 2019]. Available from: www.afrin.com/products/nasal-sprays /original-nasal-spray/.

Medicines & Healthcare products Regulatory Agency. Numark nasal decongestant spray [online]. 2016 [cited Feb 14, 2019]. Available from: www.mhr a.gov.uk/home/groups/spcpil/documents/spcpil/con1472189927174.pdf

GSK Consumer Healthcare. Otrivine [online]. 2016 [cited Feb 14, 2019]. Available from: www.medicine s.org.uk/emc/files/pil.6155.pdf

Reckitt Benckiser. Mucinex® FULL FORCE™ leaflet [online]. date unknown [cited Feb 14, 2019]. Available from: www.mucinexprofessional.com/medi a/1066/muc_fullforce_nasalspray-dfl.pdf.

Drugs.com. Vick sinex decongestant nasal spray [online]. 2017 [cited Feb 14, 2019]. Available from: www.drugs.com/uk/vicks-sinex-decongestant-nasal-spray-leaflet.html

Mori E, Merkonidis C, Cuevas M, Gudziol V, Matsuw aki Y, Hummel T. The administration of nasal drops in the "Kaiteki" position allows for delivery of the drug to the olfactory cleft: a pilot study in healthy subjects. Eur Arch Otorhinolaryngol 2016; 273: 939-43.

Kundoor V, Dalby RN. Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast. Pharm Res 2011; 28: 1895-904.

Sindwani R, Han JK, Soteres DF, Messina JC, Carothers JL, Mahmoud RA, et al. NAVIGATE I: Randomized, placebo-controlled, double-blind trial of the exhalation delivery system with fluticasone for chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy 2019; 33: 69-82.

Leopold DA, Elkayam D, Messina JC, Kosik-Gonzalez C, Djupesland PG, Mahmoud RA. NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis. J Allergy Clin Immunol 2019; 143: 126-34.e5.